Oncology billing involves the highest drug costs, the most complex prior authorization requirements, and the greatest financial risk from coding errors of any specialty. A single incorrect J-code on a $15,000 infusion can cost your practice the entire amount. We bill it correctly the first time.
Common Billing Challenges
These are the billing failure points we see most often in oncology practices — and the ones our team resolves systematically from day one.
Chemotherapy drugs must be billed with the exact J-code, dose-matched units, and NDC number. A 500mg dose of carboplatin (J9045) billed as 600mg = overpayment subject to audit and recoupment. Dose calculation from body surface area must be documented.
CMS infusion billing uses a strict hierarchy: initial hour (96413), additional hours (96415), concurrent infusion (96417), sequential (96417), push injection (96409/96411). Incorrect sequence billing is the most common oncology claim edit trigger.
When a partial vial is administered, the remaining drug must be documented as medically necessary waste. Undocumented wastage subjects the entire drug claim to denial or recoupment. CMS and commercial payers have significantly increased wastage audits in 2026.
Specialty drugs like pembrolizumab (J9271), nivolumab (J9299), and bevacizumab (J9035) require prior authorization with specific diagnosis codes, line-of-therapy documentation, and molecular testing results. First-pass auth approval rates average 68% without specialty preparation.
An E/M visit on the same day as chemotherapy infusion is separately billable if a significant separately identifiable service is performed. Modifier 25 is required on the E/M code — without it, the E/M is bundled into the infusion fee by payer edits.
Oral chemotherapy drugs (capecitabine, erlotinib, imatinib) bill under different codes and benefit designs than IV drugs. Some oral oncology drugs require FDA REMS documentation — missing REMS compliance documentation can trigger specialty pharmacy audits.
Key Procedure Codes
Our coders hold specialty-specific credentials and train continuously on the codes that drive the most revenue — and the most denials — in oncology.
| CPT Code | Description | Common Issue |
|---|---|---|
| 96413 | Chemotherapy infusion, initial hr | Hierarchy leader; concurrent adds 96417 |
| J9045 | Carboplatin injection per 50mg | Dose-matched units required; NDC mandatory |
| J9271 | Pembrolizumab per 1mg | Prior auth with biomarker testing documentation |
| 96409 | Chemotherapy push, single | 15 min+ direct supervision; distinguish from infusion |
| 99214 | Office visit, moderate complexity | Mod 25 required same-day as infusion |
| J9999 | Chemotherapy, not otherwise classified | Requires invoice and clinical documentation |
Why RCMAXIS
We are not a generalist billing service that added a specialty module. Our team is built around specialty-specific expertise.
Every J-code claim is verified against the ordered and administered dose — BSA calculations, dosing records, and vial sizes are cross-checked before submission.
Our documentation workflow captures all required wastage information automatically — protecting against the payer wastage audits that have increased significantly in 2026.
Our billing system applies the correct infusion administration hierarchy for every encounter, regardless of infusion complexity.
Prior auth packages for pembrolizumab, nivolumab, and other PD-1/PD-L1 inhibitors include biomarker testing, line-of-therapy history, and ECOG performance status documentation.
National Drug Code reporting is applied to every drug claim — with lot number and billing unit documentation as required by Medicare and commercial payers.
Systematic modifier 25 application for same-day E/M services ensures every billable physician encounter is separately captured.
Free revenue assessment for qualified practices. We audit your last 90 days of claims, identify every revenue leak, and show you a clear path to better collections — at no cost.